Jade Biosciences 株価情報 (NASDAQ: JBIO)

Jade Biosciences (NASDAQ:JBIO) 株価情報

Jade Biosciences

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Jade Biosciences Inc

News

Management

TELA

TELA Bio Appoints Jeffrey Blizard As President Effective Immediately

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/DG/earnings">bell on Tuesday, June 3.</a>
Analysts expect the company to report quarterly earnings at $1.49 per share, down from $1.65 per share in the year-ago period. Dollar General projects quarterly revenue of $10.29 billion, compared to $9.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 29, UBS analyst Michael Lasser maintained Dollar General with a Buy rating and raised the price target from $95 to $120.
With the recent buzz around Dollar General, some investors may be eyeing potential gains from the company's dividends too. As of now, Dollar General offers an annual dividend yield of 2.43%, which is a quarterly dividend amount of 59 cents per share ($2.36 a year).
To figure out how to earn $500 monthly from Dollar General, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Dollar General's $2.36 dividend: $6,000 / 2.36 = 2,542 shares.
So, an investor would need to own approximately $247,210 worth of Dollar General, or 2,542 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.158 = 508 shares, or $49,403 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DG Price Action: Shares of Dollar General gained by 0.2% to close at $97.25 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38289870/top-5-tech-and-telecom-stocks-that-may-rocket-higher-this-month">Top 5 Tech And Telecom Stocks That May Rocket Higher This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From Dollar General Stock Ahead Of Q1 Earnings

WIIM

ARVN

Arvinas shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $10 to $9.

TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading golf technology company, today announced that the Nasdaq Hearings Panel has granted the company an extension of time to comply with Nasdaq listing rules subject to panel conditions. The Company's listing will be transferred to the Capital Market, effective at the open of business on June 3, 2025.&nbsp;

TRUG

TruGolf Secures Nasdaq Compliance Extension, Subject To Panel Conditions

Galloway Capital Partners And Affiliate, Diveroli Investment Group, Announces 4.31% Stake in Babcock & Wilcox Enterprises

KURA

Kura Oncology shares are trading higher after the company announced the  FDA has granted it acceptance and priority review for Ziftomenib.

Litchfield Hills analyst Theodore O'Neill initiates coverage on Inspira Technologies Oxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) with a Buy rating and announces Price Target of $2.

Price Target

Initiation

Analyst Ratings

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Litchfield Hills Initiates Coverage On Inspira Technologies Oxy with Buy Rating, Announces Price Target of $2

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance
Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors.

ERAS

Erasca Secures FDA Clearance For First-In-Class Pan-KRAS Inhibitor ERAS-4001

LQDA

Liquidia shares are trading higher after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.

Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Chronic Rhinosinusitis (CRS)</a>.
The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (p=0.0078) in patients without nasal polyps.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44083934/amgen-astrazeneca-partnered-asthma-drug-shows-rapid-and-sustained-effect-in-chronic-rhinosinusitis" rel="noreferrer noopener">Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis</a>
The ENLIGHTEN 2 trial also met the key secondary endpoints of 3CS at 24 weeks in the full population (i.e., patients with and without nasal polyps) and in the clinically validated SNOT-22 score at 24 weeks, with symptom improvement <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717754/lyra-therapeutics-reports-positive-results-from-the-enlighten-2-phase-3-trial-of-lyr-210-achieving" rel="noreferrer noopener">observed as early as week 4</a>.
<ul class="wp-block-list">
<li>Improvements in SNOT-22 were sustained throughout the trial and were clinically meaningful. More than twice the minimal clinically important difference was observed at week 24 compared to baseline in the LYR-210 group (-22.4 points).</li>
</ul>
Consistent with previous studies, LYR-210 was well-tolerated, with a safety profile similar to sham control.
Data evaluating computed tomography (CT) scans demonstrated numerical improvement in ethmoid sinus opacification in patients who received LYR-210, compared to sham control at week 20 (-2.15; p=0.1809). These data provide objective radiological evidence of improvement with LYR-210 treatment.
<ul class="wp-block-list">
<li>LYR-210 patients showed no difference from sham patients in using corticosteroid rescue medication; however, the LYR-210 patients had fewer endoscopic sinus surgeries than sham control.</li>
</ul>
LYR-210 was well tolerated, with no product-related serious adverse events in the ENLIGHTEN 2 trial.
The ENLIGHTEN program consists of two Phase 3 trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR-210 for CRS.
<ul class="wp-block-list">
<li>While the ENLIGHTEN 2 trial met its primary endpoint and key secondary endpoints, the ENLIGHTEN 1 trial did not meet the primary or secondary endpoints, as&nbsp;<a href="https://www.benzinga.com/news/24/05/38642703/why-lyra-therapeutics-stock-is-down-93-today" target="_blank" rel="noreferrer noopener">reported&nbsp;in May 2024</a>.</li>
</ul>
Lyra also conducted a pooled data analysis of 64 CRS patients with small nasal polyps (grade 1) from the ENLIGHTEN 1 and ENLIGHTEN 2 trials. The data demonstrated a consistent positive trend compared to sham control over 24 weeks in multiple endpoints:
<ul class="wp-block-list">
<li>Improvement in 3CS with LYR-210 compared to sham control at week 24, starting as early as week 4.</li>
<li>Improvement in SNOT-22 score with LYR-210 compared to sham control at week 24, starting as early as week 4.</li>
<li>Improvements in percent ethmoid opacification with LYR-210 compared to sham control at week 20.</li>
<li>Improvements in nasal congestion score (NCS) with LYR-210 compared to sham control at week 24 for patients with moderate to severe NCS at baseline, starting as early as week 4.</li>
<li>Improved nasal polyp score with LYR-210 compared to sham control at week 24.</li>
</ul>
In March,&nbsp;the Food and Drug Administration (FDA) accepted for review&nbsp;GSK plc's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) marketing application for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44084214/gsk-twice-yearly-depemokimab-reduces-nasal-polyp-size-improves-symptoms-in-chronic-rhinosinusitis-goes-under-fda-review-for-two-indications" rel="noreferrer noopener">depemokimab in two indications</a>:
<ul class="wp-block-list">
<li>Add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller</li>
<li>Add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).</li>
</ul>
Price Action: LYRA stock is up 411.6% at $25.22&nbsp;during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/05/45703024/pfizer-reports-survival-gains-in-colorectal-cancer-study-combo-therapy-cuts-death-risk-by-over-50" target="_blank" rel="noreferrer noopener">Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

LYRA

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

TRVI

Trevi Therapeutics shares are trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.

BlueLinx Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>), a leading U.S. wholesale distributor of building products, and Louisiana-Pacific Corporation ((LP Building Solutions, NYSE:<a href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>), a leading manufacturer of engineered wood building products, are pleased to announce the expansion of their distribution partnership to Springfield, Missouri. The expanded collaboration will include LP's renowned Siding Solutions brands and prefinished solutions, namely LP&#xAE; SmartSide&#xAE; Trim &amp; Siding and LP&#xAE; SmartSide&#xAE; ExpertFinish&#xAE; Trim &amp; Siding. This strategic move expands BlueLinx's stocking footprint of LP&#xAE; SmartSide&#xAE; to 19 locations, spanning five of BlueLinx's regions across the United States.
 &nbsp;

BlueLinx Holdings And LP Building Solutions Announce Expansion Of Distribution Partnership To Springfield, Missouri

Barclays analyst Andrew Mok downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and lowers the price target from $84 to $65.

Downgrades

Barclays Downgrades Centene to Equal-Weight, Lowers Price Target to $65

ATAI

atai Life Sciences shares are trading higher after the company announced it will merge with Beckley Psytech through a share combination agreement.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Most 22-year-olds don't have to worry about their dad being Bill Gates when they bring someone home—but <a href="https://www.benzinga.com/personal-finance/24/12/42648634/bill-gates-says-his-22-year-old-daughter-told-him-to-never-email-her-so-now-he-sends-her-a-text-letting-her-know-hes-emailing">Phoebe Gates does</a>. And according to her, it's a little bit hilarious… unless you're the guy.
In an <a href="https://youtu.be/PFT7VOPWkF0?si=sfpA5TD5C6JNy0uq">appearance on the "Call Her Daddy" podcast</a> last month, Phoebe sat down with host Alex Cooper—alongside climate activist and business partner Sophia Kianni—to talk about launching their own podcast, "The Burnouts."&nbsp;
But the internet had other priorities: her stories about introducing dates to her famously introverted dad at <a href="https://www.benzinga.com/personal-finance/25/03/44207591/bill-gates-is-a-divorced-grandpa-living-alone-in-gigantic-66000-sq-ft-home-but-wont-be-downsizing-i-cant-i-like-the-houses-i-have">his $63 million lakefront high-tech mansion</a> in Medina, Washington.
"Terrifying, for the guy. For me? Hilarious."
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
That's how Phoebe summed it up. "My dad's, like, pretty socially awkward—he's said he has Asperger's," she explained on the podcast. "To me, it's so funny, but for guys, I think they get, like, really wigged out."
Phoebe didn't just tell—it was full storytime. One of the standout memories? A high school dance.
"My mom had signed my dad up to drive me and the boy to the dance together," she said. "First off, my dad insisted on us listening to NPR the entire 30-minute drive. He stopped for fast food, then he calls the guy—he's like, ‘Be responsible tonight, Max Demonhower.' His name was Maxwell Danenhower. Literally wanted to die."
For Phoebe, these awkward encounters have turned into a kind of test. "Depending on how he reacts, that's how you know if he's gonna be a good guy or not," she told Cooper. If someone can survive a socially anxious Bill Gates mispronouncing their name inside a high-security estate—maybe they're worth keeping around.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Phoebe also joked that she's the life of the party in a family of self-proclaimed nerds. "It used to be a joke our family would be so boring if I wasn't born," she said. "At the dad-daughter dances my mom would have us go to, I would force my dad to go talk to all the other dads and daughters there. I was like, ‘No. If we're here, we're going to socialize. We've got to work this room, Bill.'"
And don't even try to challenge them to a game night. "You do not want to play a board game with the two of us," she warned. "That's actually worse than introducing a guy to my dad."
Bringing home a date is nerve-wracking enough. Bringing them into a tech billionaire's $63 million mansion where they'll be grilled by a man who <a href="https://www.benzinga.com/personal-finance/25/05/45210851/bill-gates-daughter-says-she-literally-never-hears-him-talk-about-microsoft-and-finds-it-so-funny-he-wouldnt-let-her-drop-out-like-he-di">co-founded Microsoft </a>and prefers NPR over small talk? Brutal.
But Phoebe's take? If they can't handle that, they probably weren't "the guy" anyway.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

Bill Gates' 22-Year-Old Daughter Says It's 'Terrifying' For The Boys She Brings Home to Meet Her 'Socially Awkward' Dad in His $63 Million Mansion

KYMR

Kymera Therapeutics shares are trading higher after the company announced clinical data for its Phase 1 Healthy volunteer study of KT-621.

Leerink Partners analyst Andrew Berens downgrades Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) from Outperform to Market Perform and lowers the price target from $10 to $9.

Leerink Partners Downgrades Arvinas to Market Perform, Lowers Price Target to $9

Stifel analyst Brian Brophy maintains Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) with a Buy and raises the price target from $130 to $141.

Stifel Maintains Buy on Limbach Holdings, Raises Price Target to $141

VERA

Vera Therapeutics shares are trading higher after the company announced its ORIGIN Phase 3 trial has met its primary endpoint.

Press Releases

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

Earnings

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Comments

Jade Biosciences

ニュース

パートナーシップ

ベンジンガ・グローバル